Grace Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Grace Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2019 to Q3 2024.
  • Grace Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$4.83M, a 131% decline year-over-year.
  • Grace Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$16.1M, a 67.1% increase year-over-year.
  • Grace Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$12.9M, a 75.4% increase from 2022.
  • Grace Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$52.2M, a 235% decline from 2021.
  • Grace Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$15.6M, a 5.06% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$16.1M -$4.83M -$2.74M -131% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$13.4M -$4.96M -$509K -11.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$12.9M -$3.26M +$34.8M +91.4% Jan 1, 2024 Mar 31, 2024 10-K 2024-06-21
Q4 2023 -$47.7M -$3.04M +$1.2M +28.3% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-12
Q3 2023 -$48.9M -$2.09M +$3.02M +59% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$51.9M -$4.45M +$276K +5.84% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$52.2M -$38.1M -$33.7M -765% Jan 1, 2023 Mar 31, 2023 10-K 2024-06-21
Q4 2022 -$18.5M -$4.25M +$229K +5.12% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 -$18.7M -$5.11M -$1.54M -43.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$17.2M -$4.73M -$1.59M -50.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$15.6M -$4.4M -$2.1M -91.4% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-23
Q4 2021 -$13.5M -$4.47M -$2.51M -128% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 -$11M -$3.57M +$4.47M +55.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$15.4M -$3.15M +$976K +23.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$16.4M -$2.3M +$1.73M +42.9% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-21
Q4 2020 -$18.2M -$1.96M +$4.18M +68% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 -$22.3M -$8.03M -$1.78M -28.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$20.6M -$4.12M +$3.89M +48.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$24.4M -$4.03M Jan 1, 2020 Mar 31, 2020 10-K 2021-06-22
Q4 2019 -$6.15M Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 -$6.26M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$8.01M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.